CEO: Kevin Charles Gorman

Sector: Health Technology
Industry:Biotechnology

Exchange: NASDAQ

Country: US

Description: Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.


Key numbers

Market Capitalization:11221818684
Shares Outstanding: 92865100
Float: 91713851
Next Earning Date:2020-08-03
TTm EPS: 1.92
TTm Dividend Rate:
200 days moving average:107.53
50 days moving average: 124.41
One day percent Change: 2.2



2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31,
2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,